GIP and GLP-1 in Type 1 Diabetes

Last updated: July 10, 2015
Sponsor: Mikkel Christensen
Overall Status: Completed

Phase

N/A

Condition

Hormone Deficiencies

Diabetes (Pediatric)

Treatment

N/A

Clinical Study ID

NCT01739283
H-2-2009-078 33269
  • Ages 18-50
  • Male

Study Summary

Investigation of Glucose-dependent Insulinotropic Polypeptide (GIP) effects at hyper and hypoglycemia in type 1 diabetes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

• Diagnosed with type 1 diabetes (WHO criteria)

Exclusion

Exclusion Criteria:

  • HbA1c > 9 %

  • Liver disease (ALAT/ASAT > 2 x upper normal limit)

  • Diabetic nephropathy (s-creatinine > 130 µM or albuminuria)

  • Proliferative diabetic retinopathy (anamnestic)

  • Severe arteriosclerosis or heart failure (NYHA group III or IV)

  • Anemia

  • treatment with medication not applicable to pause for 12 hours

  • C-peptide increase after 50 g iv arginine

Study Design

Total Participants: 10
Study Start date:
July 01, 2012
Estimated Completion Date:
November 30, 2013

Connect with a study center

  • Gentofte Hospital

    Hellerup, 2900
    Denmark

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.